Evidence map›Paper›PMID 33504936›Full record

ArticleCommunications biology2021

Mapping the immune environment in clear cell renal carcinoma by single-cell genomics.

Nicholas Borcherding, Ajaykumar Vishwakarma, Andrew P Voigt, Andrew Bellizzi, Jacob Kaplan, Kenneth Nepple, Aliasger K Salem, Russell W Jenkins, Yousef Zakharia, Weizhou Zhang

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 257 papers.

0numbers the graph read from it
0cells of the map it votes in
257citing papers in PubMed
19.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

257 citing papers in PubMed, 348 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Enrichment of CD4iScience · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Therapeutic bacteria-trained NK cells confer long-term protection against cancer metastasis.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Single-Cell Pan-Cancer Atlas Reveals GPR171 as a Candidate Marker of CD8International journal of molecular sciences · 2026
    Article
  19. Article
  20. Article

197 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Nicholas Borcherding *Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA.
Ajaykumar Vishwakarma *Department of Pharmaceutical Sciences and Experimental Therapeutics, College of Pharmacy, University of Iowa, Iowa City, IA, USA.ORCID http://orcid.org/0000-0003-0823-2933
Andrew P VoigtMedical Science Training Program, University of Iowa, Iowa City, IA, USA.
Andrew BellizziDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
Jacob KaplanDepartment of Pathology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA.ORCID http://orcid.org/0000-0001-8770-485X
Kenneth NeppleHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.
Aliasger K SalemHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA.ORCID http://orcid.org/0000-0002-1923-6633
Russell W JenkinsLaboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, USA. rjenkins@mgh.harvard.edu.ORCID http://orcid.org/0000-0001-6110-2148
Yousef ZakhariaHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. yousef-zakharia@uiowa.edu.ORCID http://orcid.org/0000-0001-9480-2626
Weizhou ZhangHolden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA. zhangw@ufl.edu.ORCID http://orcid.org/0000-0002-8236-0346
University of Iowa · USUniversity of Iowa Hospitals and Clinics · USHarvard University · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0M
Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007337 · NIGMS · UNIVERSITY OF IOWA · PI GEYER, PAMELA K., LENTZ, STEVEN R · 1985 to 2020
$15.9M
Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasisR01CA260239 · NCI · UNIVERSITY OF FLORIDA · PI ZHANG, WEIZHOU · 2021 to 2025
$2.5M
Obesity, inflammation and breast cancerR01CA200673 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7M
CD177 suppresses breast-cancer development by inhibiting beta-cateninR01CA203834 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7M
Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor SpheroidsK08CA226391 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JENKINS, RUSSELL WILLIAM · 2018 to 2022
$946k
Flow Cytometry Cell SorterS10OD016199 · OD · UNIVERSITY OF IOWA · PI BALLAS, ZUHAIR K. · 2015 to 2015
$443k
The role of paracrine WNT5A/RYK in ErbB2-driven tumorigenesisF30CA206255 · NCI · UNIVERSITY OF IOWA · PI BORCHERDING, NICHOLAS · 2017 to 2020
$143k
NCI NIH HHS F30 CA206255NCI NIH HHS K08 CA226391NCI NIH HHS P30 CA086862NCI NIH HHS R01 CA200673NCI NIH HHS R01 CA203834NCI NIH HHS R01 CA260239NIEHS NIH HHS P30 ES005605NIGMS NIH HHS T32 GM007337NIH HHS S10 OD016199
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is one of the most immunologically distinct tumor types due to high response rate to immunotherapies, despite low tumor mutational burden. To characterize the tumor immune microenvironment of ccRCC, we applied single-cell-RNA sequencing (SCRS) along with T-cell-receptor (TCR) sequencing to map the transcriptomic heterogeneity of 25,688 individual CD45

Indexed as

Carcinoma, Renal CellKidney NeoplasmsAgedCase-Control StudiesCD8-Positive T-LymphocytesGene Expression Regulation, NeoplasticGenomicsHumansLymphocytes, Tumor-InfiltratingMaleSingle-Cell AnalysisTranscriptomeTumor Microenvironment

Identifiers

PMID33504936
PMCPMC7840906
OpenAlexW3123185162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.